United States Patent 11,779,571: Rifaximin Patent Scope, Claims, Expiration and Generic Risk

US Patent No. 11,779,571 protects a narrow method of using rifaximin to treat bloating in female patients with diarrhea-predominant irritable bowel syndrome, or IBS-D. The claims require the approved 550 mg three-times-daily regimen for 14 days and focus on bloating improvement within seven days. The patent does not claim rifaximin as a molecule, rifaximin tablets generally, or every use of rifaximin in IBS-D.

The patent creates a method-of-use barrier for a generic applicant whose labeling, promotional materials, or prescribing instructions encourage the patented bloating-treatment regimen in female IBS-D patients. Its practical value depends on Orange Book listing status, the patent's expiration date, the scope of any related family claims, and whether a generic applicant can obtain a label that omits the patented use.

What does US Patent 11,779,571 cover?

The patent covers a patient-treatment protocol with five cumulative requirements:

Required element	Claim limitation
Patient population	Female subject
Disease	Diarrhea-predominant irritable bowel syndrome
Symptom	Bloating associated with dIBS
Active ingredient	Rifaximin
Dose and duration	550 mg three times daily for 14 days
Claimed outcome	Treatment of bloating, including reduction from baseline
Timing limitation	Reduction achieved following seven days
Assessment method	Patient affirmatively reports reduced bloating

Independent claim 1 is the principal commercial claim. Claims 2 through 4 narrow the required clinical outcome and measurement method.

The patent is therefore a method-of-use patent rather than a composition, formulation, process, or polymorph patent. It does not prevent all sales of rifaximin. It targets a specific use of Xifaxan or an equivalent rifaximin product.

How should claim 1 be construed?

Claim 1 requires administration of 550 mg of rifaximin three times per day for 14 days to a female patient with dIBS-associated bloating.

The relevant claim elements are cumulative:

A method of treatment must be performed.
The patient must be female.
The disease must be dIBS.
Bloating must be associated with that disease.
Rifaximin must be administered at 550 mg per dose.
Administration must occur three times daily.
The course must last 14 days.
The purpose or result must be treatment of bloating.

A patient taking rifaximin for hepatic encephalopathy, uncomplicated traveler’s diarrhea, or a non-IBS gastrointestinal condition would not satisfy claim 1. A patient with constipation-predominant IBS would also fall outside the express claim language.

A course using 550 mg twice daily would not meet the literal dosing limitation. Neither would a 400 mg dose, a seven-day course, or a regimen in which the drug is taken only as needed.

The claim does not expressly require a particular rifaximin crystalline form, excipient, tablet coating, brand, manufacturer, or route of administration. A therapeutically equivalent rifaximin product could fall within the claim if it is used in the claimed manner.

What do claims 2 through 4 add?

Claim 2: reduction from baseline

Claim 2 requires that the treatment produce a reduction in bloating compared with symptoms established before treatment.

This limitation introduces a before-and-after comparison. It may require evidence that the patient's pretreatment bloating level was documented or otherwise established. The claim does not specify a numerical threshold, validated instrument, or minimum percentage reduction.

Claim 3: improvement within seven days

Claim 3 requires that the reduction in bloating be achieved following seven days of rifaximin administration.

The claim is narrower than claim 2 because it adds a temporal requirement. Evidence of improvement only at the end of the 14-day course may not establish infringement of claim 3 unless the evidence also shows that the improvement was present after seven days.

The phrase "following 7 days" can raise claim-construction questions. A court may consider whether it means on day seven, after completion of seven days, or at any point after seven days during the 14-day course. The intrinsic record, specification, prosecution history, and clinical protocol would control that interpretation.

Claim 4: affirmative patient response

Claim 4 requires an affirmative response from the subject when asked whether bloating was reduced.

This is a patient-reported-outcome limitation. It does not require a physician’s independent assessment, a laboratory result, or a specified scoring scale. The claim language suggests that a direct affirmative answer can establish the claimed response, provided the question addresses reduction in bloating and the other claim limitations are met.

The absence of a defined questionnaire creates potential evidentiary disputes. A generic patient report of feeling better may not be equivalent to an affirmative answer that bloating was reduced.

How does the patent compare with the FDA-approved Xifaxan regimen?

The approved IBS-D regimen for Xifaxan is 550 mg orally three times daily for 14 days. The dosage and duration in claim 1 therefore track the FDA-approved regimen for IBS-D.[2]

Issue	Xifaxan IBS-D labeling	US 11,779,571
Active ingredient	Rifaximin	Rifaximin
Dose	550 mg	550 mg
Frequency	Three times daily	Three times daily
Duration	14 days	14 days
Disease	IBS-D	dIBS
Bloating	Identified IBS-D symptom and clinical outcome	Express claim focus
Sex limitation	Label generally applies to IBS-D patients	Female subject required
Follow-up treatment	Label permits retreatment in certain circumstances	Claims do not expressly cover every retreatment scenario

The overlap with the approved label increases the patent’s commercial relevance. It also creates a potential skinny-label issue for generic applicants. A generic manufacturer may seek approval for non-patented indications or attempt to omit the patented bloating-related use. That strategy is difficult where the approved IBS-D indication, standard dosing instructions, and promotional materials naturally direct physicians toward the claimed use.

What is the patent landscape for rifaximin and Xifaxan?

Rifaximin has a layered patent estate. The relevant categories include the active ingredient and solid forms, manufacturing processes, IBS-D methods, hepatic encephalopathy methods, and other clinical-use patents.

Patent category	Typical scope	Relevance to US 11,779,571
Composition and solid form	Rifaximin compounds, polymorphs, crystalline forms	Can restrict manufacture or sale of a product independently
Manufacturing	Fermentation, purification, crystallization, or conversion processes	Can create supply-chain barriers
IBS-D methods	Treatment of IBS-D with rifaximin	Directly overlaps the claimed clinical use
Bloating methods	Symptom-specific IBS-D treatment	Closest claim category
Hepatic encephalopathy methods	Reduction of recurrence or treatment of hepatic encephalopathy	Separate indication and separate infringement analysis
Formulation	Tablet composition, coating, release, stability, or dosage form	Relevant only if the generic product practices the claimed formulation
Regulatory exclusivity	FDA exclusivity periods	Separate from patent rights

Earlier Xifaxan patents include patents directed to rifaximin forms and methods of treating gastrointestinal disorders. The IBS-D patent family has included patents with broader or different method claims than the female-bloating claims in US 11,779,571. A freedom-to-operate analysis must therefore review the entire live family and Orange Book listing, not only the claims reproduced in the question.

US 11,779,571 does not, on its face, claim:

A new rifaximin molecule;
A new rifaximin polymorph;
A tablet composition;
A manufacturing process;
Treatment of hepatic encephalopathy;
Treatment of traveler’s diarrhea;
Treatment of all IBS-D patients regardless of sex;
Any rifaximin dose other than the dose expressly incorporated into the claims.

What is the Orange Book status of US 11,779,571?

The Orange Book status must be determined from the current FDA Approved Drug Products with Therapeutic Equivalence Evaluations database and the product-specific patent certifications submitted by ANDA applicants.[3]

A method-of-use patent may be listed for an approved drug if it claims an approved use or dosing method. Listing does not prove that every generic product infringes. It does, however, require an ANDA applicant to address the listed patent through a Paragraph I, II, III, or IV certification, or through a section viii statement where the applicant omits the patented use.

The commercial consequences are:

A Paragraph III certification delays approval until patent expiration.
A Paragraph IV certification can trigger patent litigation.
A section viii statement may permit approval for non-patented uses if the proposed labeling successfully omits the protected indication or use.
An Orange Book listing can create a statutory 30-month stay if the patent holder sues within the applicable period.[4]

The patent’s practical blocking value is highest if it is listed against the 550 mg IBS-D product and if the generic applicant’s proposed labeling retains an IBS-D indication that cannot be separated from the claimed female-bloating use.

When does US Patent 11,779,571 lose exclusivity?

Patent expiration depends on the application’s earliest effective nonprovisional filing date, any terminal disclaimer, patent-term adjustment, and any patent-term extension. The issue date alone does not establish the expiration date.

For a US utility patent, the ordinary term is generally 20 years from the earliest effective US nonprovisional or international application date, subject to statutory adjustments under 35 U.S.C. §§ 154 and 156.[5]

The relevant exclusivity timeline is:

Exclusivity right	Determining event
Patent term	Earliest effective nonprovisional priority date
Patent-term adjustment	USPTO examination delays
Terminal disclaimer	May shorten term to an earlier related patent
Patent-term extension	Potential extension for regulatory review, if statutory requirements are met
FDA orphan exclusivity	Not generally the principal exclusivity mechanism for Xifaxan IBS-D
New chemical entity exclusivity	Does not apply in the same manner to an old active ingredient such as rifaximin
Three-year clinical-investigation exclusivity	Depends on the approved supplement and qualifying investigations

The precise expiration date for US 11,779,571 should be taken from the USPTO patent record and Orange Book listing because a family continuation, terminal disclaimer, or patent-term adjustment can materially change the date. The patent’s issuance in 2023 does not mean that it receives a new 20-year term beginning in 2023.

Which companies are likely to challenge the patent?

The principal challengers are ANDA applicants seeking approval for generic rifaximin 550 mg tablets. Historically, Xifaxan has attracted generic challenges because IBS-D and hepatic encephalopathy are large commercial indications and the 550 mg product has substantial revenue exposure.

A challenge can take several forms:

Paragraph IV invalidity challenge

The applicant may assert that the patent is invalid or not infringed. Likely invalidity theories include:

Obviousness based on the known Xifaxan IBS-D regimen;
Lack of written description for the female-specific and bloating-specific limitations;
Lack of enablement for the full scope of the claimed patient population;
Indefiniteness involving "associated with," "reduction," or "following 7 days";
Double patenting over earlier IBS-D method claims;
Failure to satisfy statutory requirements for patentable subject matter, although method-of-treatment claims generally avoid the principal concerns associated with diagnostic claims.

The strongest obviousness argument would combine the known 550 mg TID 14-day IBS-D regimen with clinical evidence that bloating improved during treatment. The patent holder would argue that the female-specific response and rapid seven-day bloating benefit were not predictable from the prior art and that the clinical result was unexpected.

Section viii carve-out

A generic applicant may attempt to omit the patented use from its labeling. That strategy has a lower probability of success if the remaining IBS-D labeling still instructs physicians to prescribe the same 550 mg TID 14-day regimen for patients whose principal symptom is bloating.

A carve-out also does not eliminate all induced-infringement risk. Marketing statements, physician communications, patient materials, reimbursement instructions, and real-world prescribing patterns may be examined in an infringement case.

Declaratory or district-court litigation

An ANDA filing containing a Paragraph IV certification can result in an infringement action under the Hatch-Waxman framework. The key defenses would concern claim construction, obviousness, written description, enablement, and the adequacy of any proposed label carve-out.[4]

How strong is the patent estate?

US 11,779,571 has a narrow claim scope but a commercially important target.

Strengths

The claimed regimen matches the approved IBS-D dosing regimen.
Bloating is a clinically relevant IBS-D symptom.
The claims are directed to treatment rather than merely diagnosis.
The claims contain multiple limitations that may make literal infringement harder to prove.
The seven-day and female-specific limitations may support an argument for a clinically differentiated result.

Weaknesses

The dose and duration were already associated with the approved IBS-D use.
Bloating is a known IBS-D symptom and may have been assessed in earlier trials.
The female limitation may be vulnerable if the prior art disclosed predominantly female IBS-D trial populations or sex-specific outcomes.
The claim does not specify a numerical bloating threshold.
Claim 4 relies on a relatively simple patient-reported response.
The patent may face obviousness and double-patenting challenges against earlier rifaximin IBS-D patents.
Narrow claims can be avoided by a carefully drafted label or prescribing strategy.

The estate is strongest as part of a patent cluster. The individual patent is less robust if treated as the sole barrier to generic entry.

What formulation patents protect rifaximin?

US 11,779,571 does not contain formulation limitations in the quoted claims. It does not specify:

Tablet composition;
Enteric coating;
Dissolution profile;
Particle size;
Crystalline form;
Excipient combination;
Stability profile;
Manufacturing process.

Formulation and solid-form patents must be analyzed separately. A generic manufacturer may avoid a formulation claim while still infringing a method claim, or it may avoid the method claim while practicing a formulation claim. The two risks are independent.

What manufacturing and geographic barriers apply?

The patent is a US right. It can restrict conduct involving manufacture, use, sale, offers for sale, or importation into the United States under 35 U.S.C. § 271.[6]

It does not directly block:

Manufacture and sale solely outside the United States;
Foreign regulatory approval;
Foreign use of rifaximin;
Export transactions that do not fall within the relevant US infringement provisions.

US manufacturing risk may remain significant because a foreign-made generic product imported into the United States can infringe method, product, or process patents. Process patents also may create separate importation exposure under 35 U.S.C. § 271(g).

What revenue exposure does the patent create?

The patent’s revenue exposure is tied to the IBS-D portion of Xifaxan sales, not to all rifaximin revenue. Xifaxan also has an FDA-approved hepatic encephalopathy indication, and a patent directed only to female IBS-D bloating does not independently block that use.

Commercial exposure depends on:

The proportion of prescriptions written for IBS-D;
The proportion of IBS-D patients treated for prominent bloating;
The ability of a generic applicant to obtain a carved-out label;
The status of earlier composition, solid-form, and method patents;
The timing of FDA approval;
Any settlement that restricts the generic launch date;
The number of approved ANDA applicants.

A generic launch could occur in one of three broad forms:

Launch scenario	Commercial effect
Full-label launch after all relevant patents expire or are defeated	Broad substitution across protected and unprotected uses
Carve-out launch excluding the patented bloating use	Partial substitution, with ongoing litigation risk
At-risk launch before final resolution	Rapid market share gain if successful, with damages and injunction risk

What litigation and settlement issues matter?

The principal litigation questions are whether:

The patent is listed in the Orange Book;
An ANDA applicant filed a Paragraph IV certification;
Salix or the relevant patent owner sued within the statutory period;
A 30-month stay applies;
The parties entered a settlement;
The settlement permits an authorized generic;
The agreed launch date applies to all claims or only selected patents;
Earlier Xifaxan patents remain enforceable after resolution of US 11,779,571.

A settlement involving one patent does not necessarily clear the entire Xifaxan patent estate. Generic entry must be modeled against every unexpired listed patent and any non-listed patent capable of supporting an infringement action.

Key Takeaways

US 11,779,571 is a narrow rifaximin method-of-use patent.
Its core coverage is female IBS-D patients with bloating treated with 550 mg rifaximin three times daily for 14 days.
Dependent claims add reduction from baseline, improvement after seven days, and an affirmative patient-reported response.
The claims do not cover rifaximin generally, all IBS-D patients, hepatic encephalopathy, or rifaximin formulations.
The patent overlaps closely with the FDA-approved Xifaxan IBS-D regimen.
A generic applicant’s principal strategies are Paragraph IV litigation, a section viii carve-out, or a settlement with a delayed launch.
The patent’s commercial strength depends on the full Xifaxan patent family, Orange Book status, terminal disclaimers, exact patent term, and any ANDA settlements.
The patent is more valuable as part of a layered estate than as an independent barrier to generic entry.

FAQs

Can a generic sell rifaximin for IBS-D while omitting the bloating use?

Potentially. A generic applicant may seek a section viii carve-out, but the proposed label and promotional conduct must avoid directing use for the patented female-bloating treatment.

Does US 11,779,571 cover male patients?

No. The quoted claims expressly require a female subject. A male patient falls outside the literal scope of these claims, although other rifaximin patents may cover treatment of IBS-D without a sex limitation.

Does a seven-day course infringe claim 1?

No, not literally, because claim 1 requires administration for 14 days. A seven-day course could raise different issues under other claims or patents, but it does not satisfy the express 14-day limitation in claim 1.

Is patient-reported bloating improvement enough for claim 4?

Claim 4 is drafted around an affirmative patient response. The evidence would still need to establish the required question, timing, patient population, disease, dose, and duration.

Does this patent block rifaximin for hepatic encephalopathy?

Not based on the quoted claims. The claims require female dIBS and bloating. Hepatic encephalopathy use must be assessed against separate method, formulation, and product patents.

References

United States Patent and Trademark Office. (2023). United States Patent No. 11,779,571, Methods of treating bloating associated with diarrhea-predominant irritable bowel syndrome.
U.S. Food and Drug Administration. (2024). Xifaxan (rifaximin) prescribing information. Salix Pharmaceuticals.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).
Patent Act, 35 U.S.C. §§ 154, 156.
Patent Act, 35 U.S.C. § 271.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010	AB	RX	Yes	Yes	11,779,571	⤷ Start Trial				TREATMENT OF BLOATING ASSOCIATED WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D) IN ADULT FEMALE SUBJECTS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009219240	⤷ Start Trial
Australia	2010292043	⤷ Start Trial
Brazil	112012005627	⤷ Start Trial
Brazil	PI0908026	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,779,571

Which drugs does patent 11,779,571 protect, and when does it expire?

Summary for Patent: 11,779,571